A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Exclusion Criteria

• •Have Class IV RA according to ACR revised criteria.
• •Have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to
• •* poorly controlled diabetes or hypertension
• •* chronic kidney disease stage IIIb, IV, or V
• •* symptomatic heart failure according to New York Heart Association Class II, III, or IV
• •* myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack, within the past 12 months before randomization
• •* severe chronic pulmonary disease, for example, requiring oxygen therapy
• •* major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to,
• •* systemic lupus erythematosus
• •* psoriatic arthritis
• •* axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis
• •* reactive arthritis
• •* gout
• •* scleroderma
• •* polymyositis
• •* dermatomyositis
• •* active fibromyalgia, or
• •* multiple sclerosis